The Impact of a Nutritional Supplement (Impryl®) on Male Fertility
Key facts
- Who runs it
- Radboud University Medical Center
- Where
- Netherlands21 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT03337360
- NTR6551
- Status
- Completed
- People taking part
- 1,200 people enrolled
- Started
- 23 Apr 2018
- Ended
- 1 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Impryl
- Placebo
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Couples with failure to conceive for at least 12 months and starting with EM or Couples starting with 1st/ 2nd/3rd cycle of IUI (with/without ovarian stimulation) or Couples starting with 1st/ 2nd/3rd cycle of IVF/ICSI
- Furthermore:
- Male with age 18-50 years
- Female partner with age 18-43 years
- Willing and able to give informed consent
Who cannot take part
- Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal sperm aspiration (PESA)
- Use of donor-, cryopreserved- or electro-ejaculated semen
- Ovulation induction (OI) without IUI
- IVF for an absolute tubal factor
- Embryo-transfers after cryopreservation
- Embryo-transfer after pre-implantation genetic diagnosis
- Known genetic abnormalities related to infertility
- Known urological abnormality such as a varicocele or bilateral cryptorchism
- Use of other vitamin supplements
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Infertility is a worldwide problem and about 10%-15% of all couples will be affected by the inability to have children. In approximately 50% of infertile couples a male factor is involved. Male infertility is of multifactorial origin. In the past decade, the role of oxidative stress on sperm has been researched thoroughly and found to be the problem in 30% to 80% of male infertility cases.
Read full original descriptionShow less
Impryl® is a nutritional supplement mainly consisting of vitamin B, which works on the metabolic system by activating the one carbon cycle and recycling of homocysteine without the use of any direct strong antioxidants.
In this study the investigators want to determine the effectiveness of nutritional supplement Impryl® in men of infertile couples on ongoing pregnancy rate, with or without assisted reproduction technology (ART).
The 2 groups in the trial
- ImprylExisting treatment, for comparison
One tablet daily for 6 months
- PlaceboPlacebo, for comparison
One tablet daily for 6 months
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Antioxidant Treatment and the Chance to Conceive in Men Seeking Fertility Care: The SUMMER Randomized Clinical Trial.JAMA network open, 2025
- Impact of a nutritional supplement (Impryl) on male fertility: study protocol of a multicentre, randomised, double-blind, placebo-controlled clinical trial (SUppleMent Male fERtility, SUMMER trial).BMJ open, 2020
- Record updated
- 28 August 2026